News

The ultrasound prevalence of NAFLD was 23% among a cohort of patients with IBD, with study results further identifying several clinical characteristics associated with IBD-NAFLD including age, gender, BMI, and waist circumference.

An analysis of data from the Veterans Health Administration provides insight into disparities in the rates of endoscopy or colonoscopy among patients with iron deficiency anemia or hematochezia.

The phase 3 trial results show brolucizumab had superior anatomic improvements compared to aflibercept, with no clinically meaningful differences in visual outcomes.

These new findings show promise for patient-reported outcomes, though additional research may be warranted to assess other measurement properties of the DermSat-7.

Nationwide data from Korea suggest abstinence from alcohol led to lower risks of clinical outcomes among patients with newly diagnosed open-angle glaucoma.

Results of the COMPACT study detail persistence rates, QoL data, and efficacy of biosimilar etanercept among patients in real-world settings.

The model uses repeated measurements of longitudinal predictors as opposed to variables collected once at baseline to assess risk of HCC after SVR.

Data from a 24-week, prospective trial conducted at a hospital in China provide insight into the effects of roxadustat on iron metabolism relative to use of ESAs in patients using peritoneal dialysis.

The approval is the first for a systemic therapy to treat desmoid tumors, offering patients an alternative to surgery.

During this interview segment, Dr. Yosipovitch discussed his overview of current PN research and a specific study he had presented at EADV.

A new analysis of Google search results provides perspective into the readability and quality of educational materials available online related to iron deficiency anemia.

Outlook Therapeutics plans to resubmit the BLA for ophthalmic bevacizumab by the end of 2024, pending the successful completion of a required additional trial.

This discussion with Dr. Yosipovitch covered findings presented at EADV 2023 on dupilumab and prurigo nodularis patients’ satisfaction.

Ocuphire's end-of-phase 2 meeting with the FDA supports APX3330's phase 3 advancement, with 3-step worsening in binocular DRSS score as the primary endpoint.

A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.

Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.

This data from the NOTUS trial is set to be submitted to the FDA alongside the phase 3 BOREAS trial data later in the year.

Real-world data from the FARETINA-AMD study show faricimab extended treatment intervals among eyes with nAMD.

Gideon Hirschfield, PhD, MB BChir, Lily and Terry Horner Chair in Autoimmune Liver Disease Research at the University of Toronto, sat down with HCPLive Hepatology to discuss the role of the microbiome in autoimmune liver disease.

This cardiology case report from Brady Pregerson, MD, features a man in his late 50s presenting with 3 days of episodic chest pain. Can you determine the correct diagnosis?

Presented at AAO 2023, a new analysis indicates racial and ethnic minoritized individuals may have a higher likelihood of neovascular glaucoma.

Rheumatoid arthritis and depression frequently occur together. Test your knowledge of what this means for patients with this quiz.

Safer discusses how symptoms and quality of life often go unaddressed in the few clinician-patient interactions about primary sclerosing cholangitis.

Lassailly discusses the role of bariatric surgery versus weight-loss treatments like semaglutide for patients with MASH.

Cynthia Levy, MD, professor of medicine at the University of Miami, provided further insight into unmet needs in PBC, the use of OCA-bezafibrate in PBC, and the significance of results from a pair of phase 2 studies presented at The Liver Meeting.

The FDA has approved the second renal denervation device in the agency's history with the approval of Medtronic's Symplicity Spyral system.

This case report from Brady Pregerson, MD, features a man in his early 70s presenting to the hospital with palpitations for the past 2 hours that started while playing a round of golf. Can you determine the most likely rhythm?

During this interview segment, Dr. Chovatiya further analyzed the updated National Psoriasis Foundation consensus statements for GPP and the future of treatment research.